Innoviva Inc. (INVA)

14.65
NASDAQ : Health Technology
Prev Close 14.65
Day Low/High 0.00 / 0.00
52 Wk Low/High 11.02 / 17.99
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 101.14M
Market Cap 1.60B
EPS 1.20
P/E Ratio 13.50
Div & Yield N.A. (N.A)

Latest News

GSK Announces Positive EU Approval For Labelling Update To Relvar Ellipta In Patients With Asthma

GSK Announces Positive EU Approval For Labelling Update To Relvar Ellipta In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI),...

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label...

Sarissa Capital Reconstitutes Innoviva Board Of Directors

Sarissa Capital Reconstitutes Innoviva Board Of Directors

Follows Termination of CEO Mike Aguiar

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOCC, FET, IMMU, INVA, KMDA, SPH Downgrades: COR, EARN, EML, ENS, MSON, MYL, NCR, OFC, PBH, PCYO, THR, UBA, UBNT, UFS, WHG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Innoviva Reports Record Fourth Quarter And Full Year 2017 Financial Results

Innoviva Reports Record Fourth Quarter And Full Year 2017 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter and full year 2017.

Innoviva To Report Fourth Quarter Financial Results On February 8 At 5:00 P.m. EDT

Innoviva To Report Fourth Quarter Financial Results On February 8 At 5:00 P.m. EDT

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017.

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

Innoviva And Sarissa Implement Court Order

Innoviva And Sarissa Implement Court Order

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery's order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of...

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta...

Innoviva Reaches Analyst Target Price

Innoviva Reaches Analyst Target Price

In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $13.00, changing hands for $13.06/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol,...

Innoviva To Participate At The Credit Suisse And Stifel Annual Healthcare Conferences In November

Innoviva To Participate At The Credit Suisse And Stifel Annual Healthcare Conferences In November

Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017: Credit Suisse 26th Annual Healthcare ConferenceNovember...

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA)...

Innoviva Reports Third Quarter 2017 Financial Results And Provides Business Updates

Innoviva Reports Third Quarter 2017 Financial Results And Provides Business Updates

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter of 2017.

Innoviva To Report Third Quarter Financial Results On October 25 At 5:00 P.m. EDT

Innoviva To Report Third Quarter Financial Results On October 25 At 5:00 P.m. EDT

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017.

Innoviva To Participate In Cantor Fitzgerald's Global Healthcare Conference On September 26

Innoviva To Participate In Cantor Fitzgerald's Global Healthcare Conference On September 26

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.

GSK And Innoviva Report Positive Headline Results From IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

GSK And Innoviva Report Positive Headline Results From IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single...

Trelegy Ellipta Approved As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The US

Trelegy Ellipta Approved As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The US

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone...

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion From The CHMP In Europe For Appropriate Patients With COPD

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion From The CHMP In Europe For Appropriate Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

Positive Results From Pioneering Salford Lung Study In Asthma Published In The Lancet, And Presented At European Respiratory Congress

Positive Results From Pioneering Salford Lung Study In Asthma Published In The Lancet, And Presented At European Respiratory Congress

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at...

Innoviva To Participate In Morgan Stanley's Global Healthcare Unplugged Conference On September 12

Innoviva To Participate In Morgan Stanley's Global Healthcare Unplugged Conference On September 12

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.

Innoviva Reaches Analyst Target Price

Innoviva Reaches Analyst Target Price

In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $12.80, changing hands for $12.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Innoviva Completes Refinancing Of Its 9% 2029 Non-Recourse Notes

Innoviva Completes Refinancing Of Its 9% 2029 Non-Recourse Notes

Innoviva, Inc. ("Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 million Term B Loan (the "Term B Loan"), the proceeds of which were used to repay the remaining balance of the Company's LABA...

Innoviva, Inc. Announces Closing Of $175 Million Offering Of 2.50% Convertible Senior Notes And Exercise Of The Initial Purchasers' $17.5 Million Over-Allotment Option

Innoviva, Inc. Announces Closing Of $175 Million Offering Of 2.50% Convertible Senior Notes And Exercise Of The Initial Purchasers' $17.5 Million Over-Allotment Option

Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.

Innoviva, Inc. Prices Offering Of $175 Million Of 2.50% Convertible Senior Notes

Innoviva, Inc. Prices Offering Of $175 Million Of 2.50% Convertible Senior Notes

Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.

Innoviva Announces Proposed Offering Of $175 Million Of Convertible Senior Notes

Innoviva Announces Proposed Offering Of $175 Million Of Convertible Senior Notes

Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due...

Innoviva Reports Strong Second Quarter 2017 Financial Results

Innoviva Reports Strong Second Quarter 2017 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter of 2017.

GSK Submits EU Filing For Extended Use Of Relvar Ellipta In Patients With Controlled Asthma On An ICS/LABA Combination

GSK Submits EU Filing For Extended Use Of Relvar Ellipta In Patients With Controlled Asthma On An ICS/LABA Combination

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol,...

TheStreet Quant Rating: B- (Buy)